Cogent Biosciences, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-96.4M | $-97.4M | $-102.5M | $-80.9M | $-73.5M | $-72.0M | $-67.9M | $-70.6M |
| Depreciation & Amortization | $741.0K | $626.0K | $664.0K | $641.0K | $655.0K | $640.0K | $675.0K | $620.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $17.1M | $16.9M | $15.8M | $10.6M | $9.7M | $10.0M | $10.0M | $10.4M |
| Net Cash from Operating Activities | $-77.3M | $-86.9M | $-79.1M | $-64.3M | $-54.5M | $-66.5M | $-60.6M | $-52.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $370.0K | $449.0K | $811.0K | $65.0K | $131.0K | $547.0K | $75.0K | $280.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $14.3M | $-36.5M | $-322.8M | $-155.0M | $8.9M | $69.4M | $61.7M | $60.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $3.0M | $52.5M | $588.7M | $217.4M | $47.2M | $25.0M | $26.0K | $624.0K |
| Net Change in Cash | $-60.0M | $-70.8M | $186.8M | $-2.0M | $1.6M | $27.8M | $1.1M | $8.8M |
| Free Cash Flow | $-77.6M | $-87.3M | $-79.9M | $-64.4M | $-54.7M | $-67.1M | $-60.7M | $-52.3M |